Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12374
Title: The cost of new drugs in the treatment of hypertension--the Australian experience.
Austin Authors: Louis, William J 
Affiliation: Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Dec-1989
Publication information: Cardiovascular Drugs and Therapy / Sponsored By the International Society of Cardiovascular Pharmacotherapy; 3(6): 825-7
Abstract: The treatment of hypertension by costly new drugs such as the angiotensin converting enzyme inhibitors, means that careful monitoring of health care expenditure is essential. If drugs like simvastatin come to be widely used, costs will mount even more. New drugs cannot be used indiscriminately.
Gov't Doc #: 2518653
URI: http://ahro.austin.org.au/austinjspui/handle/1/12374
URL: https://pubmed.ncbi.nlm.nih.gov/2518653
Type: Journal Article
Subjects: Angiotensin-Converting Enzyme Inhibitors.therapeutic use
Anticholesteremic Agents.therapeutic use
Antihypertensive Agents.therapeutic use
Australia
Cost-Benefit Analysis
Humans
Lovastatin.analogs & derivatives.therapeutic use
Simvastatin
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 4, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.